Search

Reviparin

[A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469]

Antihemophilic factor, human recombinant

Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells

Chlorotrianisene

A powerful synthetic, non-steroidal estrogen. [PubChem]

Droloxifene

It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required. … Droloxifene may have an effect on bone and breast tissue because it induces apoptosis.

Turoctocog alfa

[A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104] … Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials.

Aldesleukin

This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon … Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene.

Rose bengal I-131

Gemfibrozil

[L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]

Sinapultide

[L2504] Windtree is currently developing aerosolized KL4 surfactant to treat RDS in premature infants, and thereafter, to potentially address a range of indications in neonatal, pediatric and adult … [L2502] Windtree Therapeutics plans a phase III trial for Respiratory distress syndrome in 2018.

Sodium sulfate

Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. … Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion